You are here

P&T News

August 31

Some analysts find the price “cost-effective,” while advocates decry it as “excessive”
Drug is only the second treatment available for the condition

August 30

Parasitic infection is caused by Trypanosoma cruzi
Kymriah is a Novartis CAR T-cell treatment for younger patients

August 29

Effect of the drug’s accumulation in adipose tissue also unknown
Phase 3 clinical trials in patients with severe PTSD to begin in 2018
Phase 1 trials of MEDI1341, an alpha-synuclein antibody, will begin by end of 2017
Orphan drug and fast-track status underscore significant unmet need for therapy
Study is first to assess risk through objective measure of psoriasis severity

August 28

Agency cites “troubling products” being marketed in Florida and California
Improved patient results reported with MagLev HeartMate 3 at six months
Diabetes medication now indicated to lower risk of heart attack, stroke, and CV death
Approval supports initial use in patients not previously treated with endocrine therapy
Cyltezo from Boehringer Ingelheim joins Amjevita from Amgen

August 25

New medication is an extended-release version of amantadine

August 24

Kyprolis and dexamethasone reduced risk of death in relapsed or refractory patients
New economic analysis suggests the drug is worth the $9,669 annual price tag

Pages